These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 2411310

  • 1. 5-Azacytidine increases HbF production and reduces anemia in sickle cell disease: dose-response analysis of subcutaneous and oral dosage regimens.
    Dover GJ, Charache S, Boyer SH, Vogelsang G, Moyer M.
    Blood; 1985 Sep; 66(3):527-32. PubMed ID: 2411310
    [Abstract] [Full Text] [Related]

  • 2. 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia.
    Koshy M, Dorn L, Bressler L, Molokie R, Lavelle D, Talischy N, Hoffman R, van Overveld W, DeSimone J.
    Blood; 2000 Oct 01; 96(7):2379-84. PubMed ID: 11001887
    [Abstract] [Full Text] [Related]

  • 3. Hydroxyurea induction of hemoglobin F production in sickle cell disease: relationship between cytotoxicity and F cell production.
    Dover GJ, Humphries RK, Moore JG, Ley TJ, Young NS, Charache S, Nienhuis AW.
    Blood; 1986 Mar 01; 67(3):735-8. PubMed ID: 2418898
    [Abstract] [Full Text] [Related]

  • 4. Spectrum of fetal hemoglobin responses in sickle cell patients treated with hydroxyurea: the National Institutes of Health experience.
    Rodgers GP.
    Semin Oncol; 1992 Jun 01; 19(3 Suppl 9):67-73. PubMed ID: 1379375
    [Abstract] [Full Text] [Related]

  • 5. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia.
    DeSimone J, Koshy M, Dorn L, Lavelle D, Bressler L, Molokie R, Talischy N.
    Blood; 2002 Jun 01; 99(11):3905-8. PubMed ID: 12010787
    [Abstract] [Full Text] [Related]

  • 6. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.
    Rodgers GP, Dover GJ, Uyesaka N, Noguchi CT, Schechter AN, Nienhuis AW.
    N Engl J Med; 1993 Jan 14; 328(2):73-80. PubMed ID: 7677965
    [Abstract] [Full Text] [Related]

  • 7. 5-Azacytidine acts directly on both erythroid precursors and progenitors to increase production of fetal hemoglobin.
    Humphries RK, Dover G, Young NS, Moore JG, Charache S, Ley T, Nienhuis AW.
    J Clin Invest; 1985 Feb 14; 75(2):547-57. PubMed ID: 2579100
    [Abstract] [Full Text] [Related]

  • 8. Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.
    Molokie R, Lavelle D, Gowhari M, Pacini M, Krauz L, Hassan J, Ibanez V, Ruiz MA, Ng KP, Woost P, Radivoyevitch T, Pacelli D, Fada S, Rump M, Hsieh M, Tisdale JF, Jacobberger J, Phelps M, Engel JD, Saraf S, Hsu LL, Gordeuk V, DeSimone J, Saunthararajah Y.
    PLoS Med; 2017 Sep 14; 14(9):e1002382. PubMed ID: 28880867
    [Abstract] [Full Text] [Related]

  • 9. Reticulocyte parameters and hemoglobin F production in sickle cell disease patients undergoing hydroxyurea therapy.
    Borba R, Lima CS, Grotto HZ.
    J Clin Lab Anal; 2003 Sep 14; 17(2):66-72. PubMed ID: 12640630
    [Abstract] [Full Text] [Related]

  • 10. Influence of cell cycle phase-specific agents on simian fetal hemoglobin synthesis.
    Letvin NL, Linch DC, Beardsley GP, McIntyre KW, Miller BA, Nathan DG.
    J Clin Invest; 1985 Jun 14; 75(6):1999-2005. PubMed ID: 2409112
    [Abstract] [Full Text] [Related]

  • 11. Increasing fetal hemoglobin production in sickle cell disease: results of clinical trials.
    Dover GJ, Charache S.
    Prog Clin Biol Res; 1987 Jun 14; 251():455-66. PubMed ID: 2448813
    [Abstract] [Full Text] [Related]

  • 12. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia.
    Charache S, Dover GJ, Moore RD, Eckert S, Ballas SK, Koshy M, Milner PF, Orringer EP, Phillips G, Platt OS.
    Blood; 1992 May 15; 79(10):2555-65. PubMed ID: 1375104
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. The French Study Group on Sickle Cell Disease.
    Maier-Redelsperger M, de Montalembert M, Flahault A, Neonato MG, Ducrocq R, Masson MP, Girot R, Elion J.
    Blood; 1998 Jun 15; 91(12):4472-9. PubMed ID: 9616141
    [Abstract] [Full Text] [Related]

  • 16. Increasing fetal hemoglobin in sickle cell disease: comparisons of 5-azacytidine (subcutaneous or oral) with hydroxyurea.
    Dover GJ, Charache S, Boyer SH.
    Trans Assoc Am Physicians; 1984 Jun 15; 97():140-5. PubMed ID: 6085527
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Stimulation of F-cell production in patients with sickle-cell anemia treated with cytarabine or hydroxyurea.
    Veith R, Galanello R, Papayannopoulou T, Stamatoyannopoulos G.
    N Engl J Med; 1985 Dec 19; 313(25):1571-5. PubMed ID: 2415821
    [Abstract] [Full Text] [Related]

  • 20. Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease.
    Saunthararajah Y, Hillery CA, Lavelle D, Molokie R, Dorn L, Bressler L, Gavazova S, Chen YH, Hoffman R, DeSimone J.
    Blood; 2003 Dec 01; 102(12):3865-70. PubMed ID: 12907443
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.